Impact of comorbid asthma on severity of coronavirus disease (COVID-19)

Lee, Sang Chul; Son, Kang Ju; Han, Chang Hoon; Jung, Ji Ye; Park, Seon Cheol

doi:10.1038/s41598-020-77791-8

Cited by 93 publications

(77 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By contrast, Lee et al [ 99 ] found that, although asthma was not a risk factor for poor prognosis, higher mortality was observed among those who had experienced an acute exacerbation during the previous year. Similarly, Choi et al [ 100 ] reported that a pre-existing diagnosis of asthma was associated with poor outcomes among those with COVID-19, although asthma severity and the use of asthma medications were not independent risk factors.…”

Section: Covid-19 In Patients With Eosinophil-associated Diseases Andmentioning

confidence: 94%

Eosinophils and COVID-19: diagnosis, prognosis, and vaccination strategies

Rosenberg

Foster

2021

Semin Immunopathol

View full text Add to dashboard Cite

The unprecedented impact of the coronavirus disease 2019 (COVID-19) pandemic has resulted in global challenges to our health-care systems and our economic security. As such, there has been significant research into all aspects of the disease, including diagnostic biomarkers, associated risk factors, and strategies that might be used for its treatment and prevention. Toward this end, eosinopenia has been identified as one of many factors that might facilitate the diagnosis and prognosis of severe COVID-19. However, this finding is neither definitive nor pathognomonic for COVID-19. While eosinophil-associated conditions have been misdiagnosed as COVID-19 and others are among its reported complications, patients with pre-existing eosinophil-associated disorders (e.g., asthma, eosinophilic gastrointestinal disorders) do not appear to be at increased risk for severe disease; interestingly, several recent studies suggest that a diagnosis of asthma may be associated with some degree of protection. Finally, although vaccine-associated aberrant inflammatory responses, including eosinophil accumulation in the respiratory tract, were observed in preclinical immunization studies targeting the related SARS-CoV and MERS-CoV pathogens, no similar complications have been reported clinically in response to the widespread dissemination of either of the two encapsulated mRNA-based vaccines for COVID-19.

show abstract

Section: Covid-19 In Patients With Eosinophil-associated Diseases Andmentioning

confidence: 94%

Eosinophils and COVID-19: diagnosis, prognosis, and vaccination strategies

Rosenberg

Foster

2021

Semin Immunopathol

View full text Add to dashboard Cite

show abstract

“…Les principaux facteurs associés à la létalité du COVID-19 sont résumés dans le Tableau 1 , qui reprend des données issues d’études différentes en dehors de toute vaccination, citées en références ( Tableau 1 ) [1] , [2] , [3] , [4] , [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] .…”

Section: Quels Patients De Pneumologie Sont à Risque De Covid-19 Grave ?unclassified

Vaccination COVID en pneumologie.

Blanchard¹,

Ozier²,

Janßen

et al. 2021

Revue des Maladies Respiratoires

View full text Add to dashboard Cite

“…Asthma was not a significant risk factor for respiratory failure or mortality among all COVID-19 patients. However, a history of acute exacerbation (OR = 2.63, p = 0.043) was a significant risk factor for death among COVID-19 patients with asthma [64]. In anotherstudy, asthma severity was not an independent factor for poor clinical outcomes of COVID-19, but patients with step 5 asthma had a prolonged in-hospital stay duration than those with step 1 asthma in both univariate and multivariate analyses [65].…”

Section: Severe Asthma and Covid-19mentioning

confidence: 89%

Asthma and COVID-19: a dangerous liaison?

Lombardi

Gani²,

Berti

et al. 2021

asthma res and pract

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic, caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), provoked the most striking international public health crisis of our time. COVID-19 can cause a range of breathing problems, from mild to critical, with potential evolution to respiratory failure and acute respiratory distress syndrome. Elderly adults and those affected with chronic cardiovascular, metabolic, and respiratory conditions carry a higher risk of severe COVID-19. Given the global burden of asthma, there are well-founded concerns that the relationship between COVID-19 and asthma could represent a “dangerous liaison”.Here we aim to review the latest evidence on the links between asthma and COVID-19 and provide reasoned answers to current concerns, such as the risk of developing SARS-CoV-2 infection and/or severe COVID-19 stratified by asthmatic patients, the contribution of type-2 vs. non-type-2 asthma and asthma-COPD overlap to the risk of COVID-19 development. We also address the potential role of both standard anti-inflammatory asthma therapies and new biological agents for severe asthma, such as mepolizumab, reslizumab, and benralizumab, on the susceptibility to SARS-CoV-2 infection and severe COVID-19 outcomes.

show abstract

Impact of comorbid asthma on severity of coronavirus disease (COVID-19)

Cited by 93 publications

References 50 publications

Eosinophils and COVID-19: diagnosis, prognosis, and vaccination strategies

Eosinophils and COVID-19: diagnosis, prognosis, and vaccination strategies

Vaccination COVID en pneumologie.

Asthma and COVID-19: a dangerous liaison?

Contact Info

Product

Resources

About